Equity Overview
Price & Market Data
Price: $0.444
Daily Change: +$0.0026 / 0.59%
Range: $0.41 - $0.445
Market Cap: $27,354,838
Volume: 427,111
Performance Metrics
1 Week: 17.56%
1 Month: -0.86%
3 Months: -41.93%
6 Months: -9.26%
1 Year: -78.11%
YTD: -37.57%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.